These include: Corticosteroid nasal spray. This initial treatment for nasal polyps aims to reduce the size or eliminate the ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Learn the essential facts about fungal sinus infections, from recognizing early warning signs to understanding treatment ...

Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

In this randomized controlled trial, among patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, tezepelumab more effectively reduced nasal polyp size and sinonasal symptoms ...

Bucks County specialty pharmaceutical company Optinose first started exploring mergers and licensing deals in early 2022.

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

An FDA nod 12 months ago allows it to be used by those who don’t have nasal polyps ... represents the only CRS treatment on the market for those with and without polyps. Optinose—which ...

Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...